{"filing":{"accession_number":"0001517022-26-000043","cik":"0001517022","ticker":"AKBA","company_name":"Akebia Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"akba-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000043/akba-20260617.htm"},"events":[{"id":12780,"run_id":11339,"accession_number":"0001517022-26-000043","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 filing discloses the results of Akebia's 2026 Annual Meeting of Stockholders held on June 17, 2026, including five proposals: election of three Class III directors (Adrian Adams, Michael Rogers, LeAnne M. Zumwalt), approval of a Share Increase Amendment increasing authorized shares from 375M to 525M, non-binding advisory vote on named executive officer compensation, frequency recommendation for future compensation votes, and ratification of Ernst \u0026 Young LLP as independent auditor. The disclosure of shareholder vote results is the core event, and the outcomes—particularly the significant share authorization increase and director elections—are material to investors' understanding of the company's capital structure and governance.","company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9731,"accession_number":"0001517022-26-000043","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 filing discloses the results of Akebia's 2026 Annual Meeting of Stockholders held on June 17, 2026, including five proposals: election of three Class III directors (Adrian Adams, Michael Rogers, LeAnne M. Zumwalt), approval of a Share Increase Amendment increasing authorized shares from 375M to 525M, non-binding advisory vote on named executive officer compensation, frequency recommendation for future compensation votes, and ratification of Ernst \u0026 Young LLP as independent auditor. The disclosure of shareholder vote results is the core event, and the outcomes—particularly the significant share authorization increase and director elections—are material to investors' understanding of the company's capital structure and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:52:08.814288+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9731,"accession_number":"0001517022-26-000043","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 filing discloses the results of Akebia's 2026 Annual Meeting of Stockholders held on June 17, 2026, including five proposals: election of three Class III directors (Adrian Adams, Michael Rogers, LeAnne M. Zumwalt), approval of a Share Increase Amendment increasing authorized shares from 375M to 525M, non-binding advisory vote on named executive officer compensation, frequency recommendation for future compensation votes, and ratification of Ernst \u0026 Young LLP as independent auditor. The disclosure of shareholder vote results is the core event, and the outcomes—particularly the significant share authorization increase and director elections—are material to investors' understanding of the company's capital structure and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:52:08.814288+00:00","company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","filing_date":"2026-06-22"}]}